Sangamo Therapeutics, Inc. Point Richmond Tech Center 501 Canal Boulevard Richmond, CA 94804 510-970-6000 | sangamo.com SANGAMO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS Conference Call and Webcast Schedu

SANGAMO THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Richmond, California, November 8, 2018 Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported third quarter 2018

financial results and recent business highlights.

I m pleased with our continued execution toward our vision to transform Sangamo into the

premier genomic medicines company, said Sandy Macrae, CEO of Sangamo. We ve made strong progress across our clinical development programs and look forward to potential data readouts and updates from multiple clinical trials in

coming months. We expect to complete the final steps of the acquisition of TxCell by year end, establishing our leadership in the promising field of CAR-Tregs for immunological and autoimmune diseases.

Finally, we are continuing to strengthen the leadership team with the addition of Stephane Boissel as EVP of Corporate Strategy.

The independent SMC s recommendations for the CHAMPIONS Study highlight the important progress

we ve made in this program, said Ed Conner, Chief Medical Officer of Sangamo. We believe that SB-913 may have the potential to improve upon the current standard of care for patients with MPS

II, and we look forward to presenting updated results from this clinical trial early next year.

Dr. Conner continued: Regarding SB-525, we are pleased with the SMC s recommendation for escalation to an additional dose, which is enabled by the safety profile, the lack of immunogenicity, and the dose-dependent response observed to date

across the first three dose cohorts. Our goal is to advance into the pivotal phase of development with the dose that holds the highest potential to meet the needs of patients with hemophilia A. We do not believe that others have yet presented data

that would support an optimal product profile for hemophilia A gene therapy.

Third Quarter 2018 Financial Results

For the third quarter ended September 30, 2018, Sangamo reported a consolidated net loss of $12.8 million, or $0.13 per share, compared to a net loss

of $12.4 million, or $0.15 per share, for the same period in 2017. As of September 30, 2018, the Company had cash, cash equivalents, marketable securities and interest receivable of $459.3 million.

Revenues for the third quarter ended September 30, 2018 were $23.6 million, compared to $11.8 million for the same period in 2017. The

increase came primarily from $9.0 million in revenues related to our collaboration with Kite, a Gilead Company, which included reimbursement of $2.7 million in research services. Third quarter 2018 revenues were primarily generated from

Sangamo s collaboration agreements with Kite, Pfizer and Bioverativ, a Sanofi company.

Total operating expenses for the third quarter ended

September 30, 2018 were $39.8 million, compared to $24.8 million for the same period in 2017. Research and development expenses were $28.8 million for the third quarter of 2018, compared to $18.4 million for the same period

in 2017. The increase was primarily due to manufacturing and clinical trial expenses related to the progress of our clinical development programs. General and administrative expenses were $11.0 million for the third quarter of 2018, compared to

$6.4 million for the same period in 2017. This increase was primarily due to general support of growth in our pipeline and clinical programs as well as one-time transaction cost associated with the TxCell

Financial Guidance for 2018

Sangamo will host a conference call today, November 8, 2018, at 5:00 p.m. Eastern Time, which will be open to the public. The call will also be webcast

live and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The

conference ID number for the call is 9494369. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on November 8, 2018 to

11:59 p.m. ET on November 15, 2018. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively.

The conference ID number for the replay is 9494369.

Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients lives using the Company s

platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements

contains forward-looking statements regarding Sangamo s current expectations. These forward-looking statements include, without limitation, the potential for data readouts and updates from multiple clinical trials in coming months, completion

of the acquisition of TxCell by year end, Sangamo s plan to present updated safety and efficacy data from the Alta Study after dose escalation is complete and the clinical trial has progressed to the cohort expansion phase, Sangamo s plan

to present updated results from the CHAMPIONS Study early next year; Sangamo s year-end financial guidance related to cash, cash equivalents, marketable securities and interest receivable and operating

expense. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the

dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, including the Alta study and CHAMPIONS study, whether

the final results from the Alta study and CHAMPIONS study will validate and support the safety and efficacy of SB-525 and SB-913, respectively, Sangamo s reliance

on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo

and its partners will be able to develop commercially viable product candidates. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo s operations and business

environments. These risks and uncertainties are described more fully in Sangamo s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 as filed with the Securities and Exchange Commission.

Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

Sangamo Therapeutics, Inc.

(510) 970-6000, x219

(510) 970-6000, x205

SELECTED CONSOLIDATED FINANCIAL DATA

(unaudited; in thousands, except per share data)

SELECTED BALANCE SHEET DATA